Realizing the Long-Term Vision “Vision 110”
First written in FY2023. 10 of 12 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Our group formulated the long-term vision Vision 110 (fiscal years 2023 to 2032), leading up to the Company's 110th anniversary, and defined its vision as becoming a company that contributes broadly to people's health by making the new prescription pharmaceutical business, which continuously provides high-value new drugs that meet medical needs, its core business while developing a portfolio of health-related businesses. We are working to realise this vision.」
The Company continues Vision 110 as the long-term vision for fiscal years 2023 to 2032 and has reaffirmed its vision of developing a portfolio of health-related businesses with the new prescription pharmaceutical business at its core. - FY2026-H1RestatedAnnual report
「The Group is working to achieve the long-term vision Vision 110 (fiscal 2023 to fiscal 2032) and the medium-term management plan Vision 110—Stage 1—(fiscal 2023 to fiscal 2025), formulated in fiscal 2023.」
The Company is continuing initiatives toward achieving Vision 110 and Stage1. - FY2025-H1RestatedAnnual report
「The Group is working to achieve the long-term vision Vision 110 (fiscal 2023 to fiscal 2032) and the medium-term management plan Vision 110—Stage 1—(fiscal 2023 to fiscal 2025), formulated in fiscal 2023.」
The Company is continuing second-year operations under Stage1 toward the realisation of Vision 110. - FY2024RestatedAnnual report
「To give concrete form to this vision, we formulated the long-term vision Vision 110 for the Company's 110th anniversary 10 years from now.」
Vision 110 continues as the long-term vision leading up to the Company's 110th anniversary. - FY2024-Q3RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
The Company is continuing first-year operations under Vision 110, the long-term vision for fiscal years 2023 to 2032, together with Stage1. - FY2024-Q2RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
The Company is continuing first-year operations under Vision 110, the long-term vision for fiscal years 2023 to 2032, together with Stage1. - FY2024-Q1RestatedAnnual report
「In the fiscal year marking the Group’s 100th anniversary, we launched the newly formulated long-term vision, “Vision 110 (FY2023–FY2032),” and medium-term management plan, “Vision 110—Stage 1—(FY2023–FY2025).”」
The Company reaffirmed, in its first-year business operations, that Vision 110 had been launched as the long-term vision for fiscal years 2023 to 2032. - FY2023First statedAnnual report
「We formulated a new long-term vision, “Vision 110 (FY2023–FY2032),” and aim to become a company that places a new drug business at its core, continuously provides high-value new drugs addressing medical needs, develops a portfolio of health-related businesses and contributes broadly to people’s health.」
HOPE100 was ended one year ahead of schedule, and a new long-term vision covering FY2023 through FY2032 was launched toward the 110th anniversary of the Company’s founding.